Acuamark Diagnostics
AcuamarkDx is a molecular diagnostics company focused on making early cancer detection the new standard of primary care. They have developed proprietary qPCR and machine learning-driven assays that achieve high sensitivity and specificity in detecting early-stage cancer. Their solution is more accurate, reliable, cost-effective, and scalable, with a significant societal impact. The company aims to unlock frequent, recurring monitoring for early cancer signals, similar to how heart disease, thyroid function, and diabetes are monitored. Their technology utilizes multiplexed, automated, high-throughput qPCR and dPCR with predictive ML models to detect low-abundance methylation markers. AcuamarkDx's workflow involves primary care providers ordering blood tests, screening at clinical labs, and sharing results with specialists for early, targeted cancer care, aiming to prevent millions of cancer deaths annually. They have received Series A funding and have a strong advisory team with expertise in financial strategy and clinical research.
Acuamark Diagnostics
AcuamarkDx is a molecular diagnostics company focused on making early cancer detection the new standard of primary care. They have developed proprietary qPCR and machine learning-driven assays that achieve high sensitivity and specificity in detecting early-stage cancer. Their solution is more accurate, reliable, cost-effective, and scalable, with a significant societal impact. The company aims to unlock frequent, recurring monitoring for early cancer signals, similar to how heart disease, thyroid function, and diabetes are monitored. Their technology utilizes multiplexed, automated, high-throughput qPCR and dPCR with predictive ML models to detect low-abundance methylation markers. AcuamarkDx's workflow involves primary care providers ordering blood tests, screening at clinical labs, and sharing results with specialists for early, targeted cancer care, aiming to prevent millions of cancer deaths annually. They have received Series A funding and have a strong advisory team with expertise in financial strategy and clinical research.